Compile Data Set for Download or QSAR
Report error Found 70 Enz. Inhib. hit(s) with all data for entry = 373
TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264158(US9714234, 33)
Affinity DataIC50: 0.400nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264140(4-(3-(S)-(5-Chloro-1,3-dioxo-1H-pyrido[1,2-c]pyrim...)
Affinity DataIC50: 0.410nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264137(7-(2-Hydroxypropan-2-yl)-4-(3-(5-methoxy-1,3-dioxo...)
Affinity DataIC50: 0.520nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264156(US9714234, 31)
Affinity DataIC50: 0.540nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264149(8-Fluoro-1-methyl(d3)-3-(S)-(2-methyl-3-(4,4,5,5-t...)
Affinity DataIC50: 0.590nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264136(2-(3-Bromo-2-methylphenyl)-6-methoxy-1H-pyrido[1,2...)
Affinity DataIC50: 0.630nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264150(4-(3-(S)-(8-Fluoro-1-methyl-2,4-dioxo-1,2-dihydroq...)
Affinity DataIC50: 0.700nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264151(4-(3-(S)-(8-Fluoro-1-methyl-2,4-dioxo-1,2-dihydroq...)
Affinity DataIC50: 0.840nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264130(3-(3-Bromo-2-methylphenyl)-8-fluoro-1-methyl(d3)qu...)
Affinity DataIC50: 0.900nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264146(US9714234, 22 | 4-(3-(5-Fluoro-1,3-dioxo-1H-pyrido...)
Affinity DataIC50: 0.930nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264138(5-Chloro-2-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-...)
Affinity DataIC50: 0.940nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264139(4-(3-(R)-(5-Chloro-1,3-dioxo-1H-pyrido[1,2-c]pyrim...)
Affinity DataIC50: 1nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264148(4-Bromo-7-(2-hydroxypropan-2-yl)-8-methyl-9H-carba...)
Affinity DataIC50: 1.20nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264152(4-(3-(S)-(8-Fluoro-1-methyl(d3)-2,4-dioxo-1,2-dihy...)
Affinity DataIC50: 1.20nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264155(US9714234, 30)
Affinity DataIC50: 1.20nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264135(2-(3-Bromo-2-methylphenyl)-5-methoxy-1H-pyrido[1,2...)
Affinity DataIC50: 1.40nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264126(4-(3-(8-Fluoro-2,4-dioxo-1,2-dihydroquinazolin-3(4...)
Affinity DataIC50: 1.5nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264153(US9714234, 28)
Affinity DataIC50: 1.5nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264154(US9714234, 29)
Affinity DataIC50: 1.5nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264145(4-(3-(5,7-Dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-...)
Affinity DataIC50: 1.60nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264144(5-Fluoro-2-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-...)
Affinity DataIC50: 1.60nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264146(US9714234, 22 | 4-(3-(5-Fluoro-1,3-dioxo-1H-pyrido...)
Affinity DataIC50: 1.70nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264142(4-(3-(5-Chloro-1,3-dioxo-1H-pyrido[1,2-c]pyrimidin...)
Affinity DataIC50: 1.70nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264132(7-(2-Hydroxypropan-2-yl)-4-(3-(8-methoxy-1-methyl-...)
Affinity DataIC50: 1.70nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264141(4-(3-(5-Chloro-1,3-dioxo-1H-pyrido[1,2-c]pyrimidin...)
Affinity DataIC50: 2.10nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264134(4-(3-(3-(4-Fluorophenyl)-2,6-dioxo-2,3-dihydropyri...)
Affinity DataIC50: 2.20nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264143(4-(3-(5-Fluoro-1,3-dioxo-1H-pyrido[1,2-c]pyrimidin...)
Affinity DataIC50: 2.30nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264157(US9714234, 32)
Affinity DataIC50: 2.30nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM50194721(CHEMBL3908310 | US9714234, 4)
Affinity DataIC50: 2.30nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264127(8-Fluoro-1-methyl-3-(2-methyl-3-(4,4,5,5-tetrameth...)
Affinity DataIC50: 2.40nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230144(US9714234, Comparative Ex. 34 | US9334290, Compara...)
Affinity DataIC50: 2.60nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM50194721(CHEMBL3908310 | US9714234, 4)
Affinity DataIC50: 4.40nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264131(3-(3-Bromo-2-methylphenyl)-8-methoxy-1-methylquina...)
Affinity DataIC50: 5.30nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264133((Z)-4-((3-Bromo-2-chlorophenyl)imino)-1-methyl-1H-...)
Affinity DataIC50: 5.80nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230145(US9714234, Comparative Ex. 35 | US9334290, Compara...)
Affinity DataIC50: 6.90nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, INVITROGEN Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264156(US9714234, 31)
Affinity DataIC50: 79nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230145(US9714234, Comparative Ex. 35 | US9334290, Compara...)
Affinity DataIC50: 200nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264158(US9714234, 33)
Affinity DataIC50: 226nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM230144(US9714234, Comparative Ex. 34 | US9334290, Compara...)
Affinity DataIC50: 240nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264155(US9714234, 30)
Affinity DataIC50: 430nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264154(US9714234, 29)
Affinity DataIC50: 470nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264145(4-(3-(5,7-Dioxo-5H-thiazolo[3,2-c]pyrimidin-6(7H)-...)
Affinity DataIC50: 570nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264143(4-(3-(5-Fluoro-1,3-dioxo-1H-pyrido[1,2-c]pyrimidin...)
Affinity DataIC50: 740nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264157(US9714234, 32)
Affinity DataIC50: 740nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264153(US9714234, 28)
Affinity DataIC50: 800nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264127(8-Fluoro-1-methyl-3-(2-methyl-3-(4,4,5,5-tetrameth...)
Affinity DataIC50: 850nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264146(US9714234, 22 | 4-(3-(5-Fluoro-1,3-dioxo-1H-pyrido...)
Affinity DataIC50: 880nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264146(US9714234, 22 | 4-(3-(5-Fluoro-1,3-dioxo-1H-pyrido...)
Affinity DataIC50: 960nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264137(7-(2-Hydroxypropan-2-yl)-4-(3-(5-methoxy-1,3-dioxo...)
Affinity DataIC50: 980nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM264148(4-Bromo-7-(2-hydroxypropan-2-yl)-8-methyl-9H-carba...)
Affinity DataIC50: 1.00E+3nMpH: 7.4 T: 2°CAssay Description:Compounds with activity against Jak2 tyrosine kinase have been observed to cause thrombocytopenia, anemia and neutropenia in human patients in clinic...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/15/2018
Entry Details
Go to US Patent

Displayed 1 to 50 (of 70 total ) | Next | Last >>
Jump to: